消息面上，民政部印发《关于进一步推进民政科技创新的指导意见》，其中提到，广泛应用人形机器 人、脑机接口、人工智能等前沿技术，开展失能失智预防和抗衰老、生活照料和康复护理、精神慰藉和 社会参与促进、安全风险监测和紧急救援、老年宜居环境建设和适老化改造等方面关键技术装备研发。 截至2026年1月30日 10:05，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，海思科领涨 2.62%，新产业上涨1.67%，华润三九上涨0.96%；片仔癀领跌。医疗创新ETF(516820)最新报价0.36元。 规模方面，医疗创新ETF最新规模达18.67亿元，创近1年新高。从资金净流入方面来看，医疗创新ETF 近10天获得连续资金净流入，最高单日获得4182.65万元净流入，合计"吸金"1.86亿元，日均净流入达 1857.56万元。（数据来源：Wind） 招商证券指出，脑机接口技术已从长期学术探索阶段进入产业拐点，在政策与需求双重驱动下，医疗成 为其核心主战场，占全球应用场景的56%；中国脑机接口产业在系统集成与应用落地方面进展显著， 2025年被正式纳入"十五五"规划中的"六大未来产业"，顶层设计与地方支持同步加 ...

Group 1 - The core viewpoint of the news highlights the performance of the China Securities Pharmaceutical and Medical Device Innovation Index, with stocks showing mixed results, led by Haikang and Dabo Medical, while Pianzaihuang experienced a decline [1] - The Medical Innovation ETF has seen continuous net inflows over the past 10 days, with a peak single-day net inflow of 41.83 million yuan, totaling 186 million yuan, averaging 18.58 million yuan daily [1] - Huawei Cloud is set to launch the first implementation area of its industry AI "Dream Factory" plan, focusing on smart healthcare, aiming to integrate top medical resources and cutting-edge technology [1] Group 2 - Guojin Securities notes that global pharmaceutical companies have effectively initiated AI platform construction, significantly enhancing efficiency in target discovery, molecular generation, and clinical trial design [2] - The Medical Innovation ETF closely tracks the China Securities Pharmaceutical and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies from the pharmaceutical and medical device sectors [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, and Mindray Medical, collectively accounting for 63.75% of the index [2]

Market Overview - The market has shifted back to high dividend and low valuation stocks, with a notable rebound in the "drinking and medicine" sector, particularly in pharmaceuticals and healthcare [1][12] - Major healthcare stocks such as United Imaging, WuXi AppTec, and Mindray Medical have all risen over 2%, while the largest healthcare ETF (512170) ended a three-day decline with a 1.4% increase, trading at 9.65 billion yuan [1][12] Fund Inflows - The healthcare sector has attracted significant "bottom-fishing" capital, with the healthcare ETF (512170) seeing a single-day inflow of 4.99 billion yuan, marking a total of 18 billion yuan in net inflows over nine consecutive trading days [1][14] - The ETF's current PE valuation is still below 60% of the historical range over the past decade, indicating a favorable cost-performance ratio for investors [3][14] Earnings Forecasts - Among the 14 disclosed stocks for 2025 earnings forecasts, 10 are expected to achieve double-digit growth, with Lepu Medical projecting a net profit increase of 386% [3][14] - Key players in the CXO sector, including Zhaoyan New Drug and Boteng Co., are also expected to see their profits double [3][14] AI and Healthcare - The AI healthcare sector is gaining attention, with Huawei Cloud set to launch a smart healthcare platform on February 1, which will integrate top medical resources and cutting-edge technology [3][14] Pharmaceutical Sector Performance - The pharmaceutical sector is showing significant value, with the newly released "Drug Administration Law Implementation Rules" promoting drug research and development, including fast-track approval processes for new drugs [7][18] - The pharmaceutical ETF (562050) has seen a net inflow of over 12 million yuan in the past five days, ending an 11-day decline with a slight increase of 0.59% [5][16] Company-Specific Earnings - The pharmaceutical ETF has disclosed earnings forecasts for 9 stocks, with 8 expected to see profit increases, including Tonghua Dongbao, which anticipates a 30-fold increase in net profit [7][18] - Other companies like Sanofi and Yiling Pharmaceutical are also projected to achieve significant profit growth [7][18] Investment Tools - Investors are encouraged to focus on the pharmaceutical ETF (562050) and its associated funds, which track the top 50 pharmaceutical companies in A-shares, balancing innovation and traditional medicine [7][18]

Core Insights - The medical services sector experienced a rise of 1.61% on January 29, with Tongce Medical leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Services Sector Performance - Tongce Medical (600763) closed at 47.49, with a gain of 5.14%, and a trading volume of 206,500 shares, amounting to a transaction value of 9.65 billion [1] - Other notable performers included: - Digital Human (920670) at 20.26, up 3.90%, with a transaction value of 2.08 billion [1] - Meinian Health (002044) at 7.28, up 3.70%, with a transaction value of 24.68 billion [1] - Tiger Medical (300347) at 58.91, up 3.51%, with a transaction value of 7.82 billion [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.146 billion from institutional investors, while retail investors experienced a net outflow of 1.043 billion [2][3] - Key stocks with significant capital flow included: - WuXi AppTec (603259) with a net inflow of 306 million, representing 5.87% of total capital [3] - Aier Eye Hospital (300015) with a net inflow of 228 million, representing 15.83% of total capital [3] - Meinian Health (002044) with a net inflow of 163 million, representing 6.60% of total capital [3]

Core Viewpoint - China Galaxy Securities is optimistic about the pharmaceutical industry's investment opportunities in 2026, focusing on hard technology in medicine, innovation, and overseas expansion, while seeking alpha in niche segments [1] Group 1: Investment Trends - In Q4 2025, public fund holdings in pharmaceuticals decreased, indicating an overall low allocation level [1] - The market value of pharmaceutical theme funds decreased by 9.73% to 205.9 billion yuan, which is 66.54% higher than the average since 2019 [1] - The market value of the pharmaceutical biotechnology sector fell by 18.81% to 312.5 billion yuan, with a holding ratio of 8.12%, below the historical average by 3.89 percentage points [1] Group 2: Stock Performance - The top five pharmaceutical stocks held by public funds in Q4 2025 saw significant reductions in both the number of funds and total market value, with notable declines in stocks like Heng Rui Medicine and WuXi AppTec [2] - The concentration of holdings has shifted from innovative drugs to medical devices and services, indicating a change in market investment focus [2] Group 3: Industry Data Overview - The pharmaceutical manufacturing industry's revenue has shown a slight decline, with a year-on-year decrease of 1.2% in Q4 2025 [3] - Medical service volumes remained stable, with a total of 1.86 billion outpatient visits in early 2025, reflecting a 0.1% year-on-year decrease [3] - The overall operation of the medical insurance fund has been stable, with total income of 2.632 trillion yuan and total expenditure of 2.110 trillion yuan from January to November 2025 [3] Group 4: Market Comparison - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a rolling P/E ratio of 38.19 compared to 14.14 for the CSI 300, indicating a premium of 170.14% over the index [3] - The SW pharmaceutical biotechnology index increased by 1.44% from early 2024 to January 28, 2026, while the CSI 300 rose by 37.15%, showing a relative underperformance of 35.71% for the pharmaceutical sector [3]

Group 1 - Hong Kong's capital market is projected to regain the top position in global IPO fundraising in 2025, with a total of $37.4 billion, surpassing the total of the previous three years and marking the highest level since 2021 [1] - The strong performance is driven by eight IPOs exceeding $1 billion and a diverse range of new economy companies, indicating a shift towards a more diversified market structure [1] - Newly listed stocks have shown positive performance, with an average first-day increase of 23.8% and a cumulative first-month increase of 30.7%, particularly in the biotechnology and healthcare sectors [1] Group 2 - The A+H share listing has emerged as a significant highlight, with 19 A-share companies completing H-share listings in 2025, raising $17.7 billion and enhancing the international investor base for these companies [2] - By the end of 2025, 96 A-share companies had submitted applications for listing in Hong Kong, with over 70 expressing intent to list, suggesting that A+H listings may continue to be a focus in 2026 [2] - The derivatives market is expanding alongside new stock listings, with the introduction of stock options for companies like CATL, providing investors with immediate risk management tools [2]

Market Overview - In Q4 2025, market volatility increased, with A-shares and Hong Kong stocks ending the year amidst fluctuations. The Shanghai Composite Index rose by 2.22%, while the CSI 300 Index fell by 0.23%, and the ChiNext Index decreased by 1.08%. The Hang Seng Index dropped by 4.56%, and the Hang Seng China Enterprises Index fell by 6.72% [1][18]. Sector Performance - Despite the overall market performance being lackluster, there was a stark contrast within sectors. The technology growth sectors, represented by AI computing power and semiconductors, performed exceptionally well, while industries such as real estate, pharmaceuticals, and computers faced pressure [1][19]. Fund Manager Strategies - Star fund managers like Fu Pengbo and Li Xiaoxing achieved significant excess returns in Q4 2025, with Fu's Ruiyuan Growth Value Fund and Li's Yinhua Small Cap Select both rising over 60% for the year, driven by heavy investments in AI computing power and semiconductors [2][19]. - Balanced allocation funds, such as Zhu Shaoxing's Fuguo Tianhui Select Growth A, showed stable performance with over 20% annual growth, benefiting from diversified holdings across finance, consumption, and manufacturing sectors [2][19]. Technology Sector Focus - Fu Pengbo's Ruiyuan Growth Value Fund increased its allocation to data center liquid cooling and related companies, with the top ten holdings now concentrated at 70.38%. The fund's top three holdings include Xinyi Solar, Shenghong Technology, and CATL [4][22]. - Li Xiaoxing's Yinhua Small Cap Select emphasized AI hardware innovation and application investment opportunities, with seven of its top ten holdings in the semiconductor industry, reflecting a shift towards advanced process breakthroughs and domestic chip investments [23][24]. Traditional Value Sector - Fund managers like Zhang Kun, Liu Yanhun, and Ge Lan continued to focus on traditional assets such as consumption and pharmaceuticals. Zhang's E-Fund Blue Chip Select maintained a stable stock position, emphasizing confidence in the long-term prospects of the Chinese consumer market [24][25]. - Ge Lan's China Europe Medical Health A faced net value pressure in Q4 2025, with all top ten holdings experiencing negative returns, despite previous positive performance [26][27]. Policy and Market Sentiment - Fund managers noted that "anti-involution" policies are becoming key variables affecting corporate fundamentals, with expectations for improved business environments and competition dynamics [31]. - Despite market rebounds and rising valuations, many managers believe that equity assets still hold significant allocation value, particularly in light of changes in traditional high-yield channels [32]. Importance of Stock Selection - The emphasis on stock selection has intensified, with fund managers highlighting the need for deep research and careful selection of companies with core advantages, especially in a concentrated market environment [33].

Core Viewpoint - The article highlights the significant divergence in performance among various sectors in the Chinese stock market during Q4 2025, with technology and growth sectors like AI computing and semiconductors outperforming traditional sectors such as real estate and pharmaceuticals [1][2][4]. Summary by Sections Market Performance - In Q4 2025, the Shanghai Composite Index rose by 2.22%, while the CSI 300 Index fell by 0.23%, and the ChiNext Index decreased by 1.08%. The Hang Seng Index dropped by 4.56%, and the Hang Seng China Enterprises Index fell by 6.72% [1]. Fund Manager Strategies - Star fund managers like Fu Pengbo and Li Xiaoxing achieved significant excess returns, with Fu's Ruiyuan Growth Value Fund and Li's Yinhua Small Cap Select both rising over 60% in 2025, driven by heavy investments in AI computing and semiconductors [1][2]. - Balanced allocation funds, such as Zhu Shaoxing's Fuguo Tianhui Select Growth A, showed stable performance with over 20% annual growth, benefiting from diversified holdings across multiple sectors [2][12]. Technology Growth Focus - Funds focusing on technology growth, like those managed by Fu Pengbo and Xie Zhiyu, saw rewards for their strategies, with increased allocations to data center cooling, storage, and computing-related companies [4][5]. - Li Xiaoxing emphasized AI as a key investment theme, with a strong focus on semiconductor companies, indicating a shift towards domestic advanced processes and military-civilian integration opportunities [6]. Traditional Value Sector - Fund managers like Zhang Kun and Liu Yanhun maintained positions in traditional sectors like consumer goods and pharmaceuticals, facing significant net value pressure in Q4 2025. Liu's fund saw a decline of 5.85% in Q4, while Zhang's fund remained stable but adjusted sector allocations [8][10]. - Despite challenges, the pharmaceutical sector showed signs of improvement due to policy changes and innovation, with opportunities emerging in innovative drug chains and medical devices [9][10]. Consensus Among Fund Managers - Despite differing investment styles, fund managers shared common views on the impact of "anti-involution" policies on corporate fundamentals and the relative attractiveness of equity assets in the current market environment [16][17]. - The importance of stock selection has increased significantly, with a focus on identifying core companies with competitive advantages in both growth and value sectors [17].

全球脑机接口玩家奋楫争先，产业化落地谱写投资蓝图 20260128 摘要 创新药领域，减肥、小核酸及 2L 疗法值得关注。减肥和 IO 赛道市场规 模达千亿美元级别，具弹性机会。小核酸赛道也因高景气度备受关注。 全年维度来看，医药板块值得重点关注。 脑机接口商业化处于起步阶段，是 2026 年投资主线。植入式临床进展 迅速，心伟医疗、爱鹏医疗和乐普医疗安全性具优势。非侵入式方面， 翔宇、迈兰德、创新医疗和诚益通等公司靠前。 政策支持对脑机接口行业发展起到重要引领作用，2025 年推出发展目 标与产业规划蓝图，确立收费项目立项，提高公立医院购买积极性，为 未来纳入医保铺平道路。 脑机接口产业链核心技术壁垒集中于中上游，包括硬件（电极、芯片）、 手术机器人及算法处理等。国产替代进程加速，美好医疗率先卡位上游 并开始代工侵入型电极。 Neuralink 需定制 ASIC 芯片，因通用芯片无法在处理上千通道信号的 同时控制功耗。其关键部分是模拟前端，需实现微弱神经信号的放大、 滤波和数字化。 Q&A 目前医药板块的投资机会主要集中在哪些方向？ 当前医药板块的投资机会主要集中在创新药及其相关产业链上。尤其是一些龙 头企 ...

Core Viewpoint - The Shanghai 180 ETF Index Fund (530280) has shown a positive performance with a recent increase of 0.71% over the past week and a 14.83% rise over the last six months, indicating strong market interest and potential investment opportunities [1][2]. Performance Summary - As of January 28, 2026, the Shanghai 180 ETF Index Fund has achieved a maximum monthly return of 9.13% since its inception, with the longest consecutive monthly gain being 6 months and a total gain of 22.51% during that period [2]. - The fund has a historical average monthly return of 3.08%, with a monthly profit percentage of 72.73% and a monthly profit probability of 74.89% [2]. - The fund has maintained a 100% probability of profit over a one-year holding period since inception, with an annualized return exceeding the benchmark by 2.31% [2]. Risk and Fee Analysis - The maximum drawdown for the fund this year is 1.30%, with a relative benchmark drawdown of 0.06%, indicating a relatively stable performance [3]. - The management fee for the fund is 0.15%, and the custody fee is 0.05%, which are among the lowest in comparable funds [3]. - The tracking error over the past three months is 0.018%, demonstrating high tracking precision compared to similar funds [3]. Index Composition - The Shanghai 180 Index consists of 180 securities selected from the Shanghai market, reflecting the overall performance of core listed companies [3]. - As of December 31, 2025, the top ten weighted stocks in the index include Kweichow Moutai, Zijin Mining, and China Ping An, collectively accounting for 25.29% of the index [3].